Biopharma firm IN8bio's Q2 net loss narrows as expenses decline
IN8bio Inc expected to post a loss of 37 cents a share - Earnings Preview
Brief: IN8BIO - Enters Capital On Demand Sales Agreement With Jonestrading For ATM Offering
IN8bio Q1 net loss narrows as R&D expenses fall
IN8bio Q4 net loss narrows, cash position more than doubles
Brief: In8bio Says Jeremy Graff Appointed Interim Chair Of Board
Brief: In8bio Announces Pricing Of Private Placement Of Up To $40.2 Million
Brief: In8bio Inc Files For Mixed Shelf Offering Of Upto $200 Million - SEC Filing
IN8bio Q3 net loss narrows to $3.9 mln, R&D expenses down
Brief: IN8bio Expands INB-100 Phase 1 Clinical Trial with Addition of The Ohio State University as New Site
Brief: In8bio Presents T Cell Engager Data Demonstrating Deep B Cell Depletion For Autoimmune Indications
IN8bio Inc reports results for the quarter ended June 30 - Earnings Summary
IN8bio Inc expected to post a loss of $1.80 a share - Earnings Preview
Brief: In8bio Presents Positive Phase 1 Data Of Inb-200 In Newly Diagnosed Gbm Demonstrating Prolonged Progression-Free Survival
Brief: IN8BIO Q4 Net Income USD -6.4 Million
U.S. STOCKS ON THE MOVE-Marriott International, Coty, Carlyle Group
IN8bio rises on early-stage data from cancer therapy
U.S. RESEARCH ROUNDUP-Cisco, Freshpet, Nvidia
Brief: Aigh Capital Management, Llc Reports 9.3% Passive Stake In In8bio, Inc. As Of Oct 1